Adjusted comparison of teclistamab versus physician's choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma Meeting Abstract
| Authors: | Mateos, M. V.; Chari, A.; Usmani, S.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; Ammann, E.; Kobos, R.; Smit, J.; Parekh, T.; Marshall, A.; Slavcev, M.; Moreau, P. |
| Abstract Title: | Adjusted comparison of teclistamab versus physician's choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma |
| Meeting Title: | 19th International Myeloma Society Annual Meeting (IMS) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. |
| Meeting Dates: | 2022 Aug 25-27 |
| Meeting Location: | Los Angeles, CA |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-08-01 |
| Start Page: | S192 |
| End Page: | S193 |
| Language: | English |
| ACCESSION: | WOS:000895909200337 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(22)00611-5 |
| Notes: | Meeting Abstract: P-281 -- Source: Wos |
